Among the most important changes in diabetes management in the last generation is the dramatic clinical benefits produced by select glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium glucose cotransporter-2 (SGLT2) inhibitors. This evidence concerns the gene GLP1R and diabetes mellitus.